יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Integra LifeSciences Inc. (IART)

The historical EV/EBITDA chart for Integra LifeSciences (IART) visualizes the link between market value and its strategy of neurosurgery dominance through the sale of Codman consumables. Manufacturing capacities in Europe and the US ensure the stable production of complex implants. The value of 8.13 represents the current metric level, confirming business resilience due to the deep integration of brands into clinics, which protects the company from competitors.

For Integra LifeSciences (IART), the ratio of enterprise value to operating profit reflects capitalization resilience inclusive of debt amid margin volatility in the neurosurgery segment and product recall risks. By analyzing the business valuation via the EV/EBITDA multiple, an investor determines how efficiently assets generate income relative to total liabilities, which is critical when assessing the success of new biomaterials and FDA approvals.